Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats.
about
Is lipid signaling through cannabinoid 2 receptors part of a protective system?Measurement of cardiac function using pressure-volume conductance catheter technique in mice and ratsCirrhotic cardiomyopathyHepatosplanchnic circulation in cirrhosis and sepsisFatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disordersOpioid receptors blockade modulates apoptosis in a rat model of cirrhotic cardiomyopathy.Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats.β-AR blockers suppresses ER stress in cardiac hypertrophy and heart failure.Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids.Endocannabinoids in liver disease.The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openingsUpdate on the role of cannabinoid receptors after ischemic stroke.Cannabinoid receptors in acute and chronic complications of atherosclerosis.Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioningEndocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseasesModulating the endocannabinoid system in human health and disease--successes and failuresThe endocannabinoid system and liver diseases.Targeting the endocannabinoid system: to enhance or reduce?Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis.Estrogen-related receptor γ controls hepatic CB1 receptor-mediated CYP2E1 expression and oxidative liver injury by alcohol.Blunted cardiac response to hemorrhage in cirrhotic rats is mediated by local macrophage-released endocannabinoidsThe heart and the liver.Endocannabinoids and cardiac contractile function: pathophysiological implications.Endocannabinoids and the heart.Endocannabinoids and the cardiovascular response to stress.The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives.Fatty acids and cardiac disease: fuel carrying a message.Cirrhotic cardiomyopathy: a cardiologist's perspective.Recent advances in cirrhotic cardiomyopathy.Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.Molecular Mechanisms Leading to Splanchnic Vasodilation in Liver Cirrhosis.Role of cannabinoids in chronic liver diseases.QT interval prolongation in end-stage liver disease cannot be explained by nonhepatic factors.Anandamide preserves cardiac function and geometry in an acute doxorubicin cardiotoxicity rat model.Deficiency of type 1 cannabinoid receptors worsens acute heart failure induced by pressure overload in mice.
P2860
Q24633122-2EA271D8-EBFE-471B-B6FF-73A547AF401EQ24648818-CB422443-406C-4923-BA46-365778B37D19Q26778048-C7FC8EDF-B14C-4305-A1A3-D386FCBF1EB9Q26864350-14BAB83C-8515-4599-90E8-167F658B6EEDQ28285103-12797C05-128B-454A-B35F-F12497910B36Q33809536-B986AA1E-47D2-44A8-BF6A-E1C9F68575AFQ33920996-BAFB4443-D762-447A-B329-4D1F4B40D54FQ34071906-77ED8FD9-2A5F-4BA9-8329-27ACE74EB2FBQ34216434-783E3CD1-346E-4315-9B70-DCA920F9111AQ34776919-98A10443-3493-4864-90FC-8CBC33CC03CEQ35193292-D554878F-D201-4F28-AF6A-BB7C2D28F81FQ35915645-B8F42CAF-5B52-40C7-AA2F-191610F6E8DCQ36416368-49F922A1-B70C-4565-8E0D-4F02D1280253Q36416372-078FA6ED-9609-442A-BFCF-A9A44D889261Q36647969-DE39ACF1-1D1A-4564-AEF9-0E03F030EAE2Q36933683-4C6C534C-83F6-41DC-98FD-F7480726CFB7Q37143574-73248B54-6F17-4C1B-AACA-D54E8C00939FQ37150745-3E734405-8EEA-485C-A478-E82279A966BEQ37243665-D759B0C7-6EBD-4583-9843-882056A5AE21Q37266999-AC49F1B3-C99B-43AA-B38E-7BE9EEEAEC3FQ37301437-278F9D2A-D6ED-41A0-8993-6221FCF801F6Q37390649-617D8C6B-A5B1-4AA2-BC8A-C3C678EB514BQ37401757-C312CF9A-0C89-454A-9F4F-5A690B73FD38Q37412217-D858FBB6-0CFE-4D67-8372-8887D1388778Q37894978-57115A71-3D68-481D-B78B-FEE416D0379DQ38124458-D28ECF6F-11FC-48E2-82E2-3A7F3B94C110Q38207743-BFFA9302-2393-4D5C-9E04-9F2B4B15E4B3Q38268611-547006FA-3A72-45ED-8690-BDF11042BEE7Q38268965-FF0FABDA-F582-4CB8-81F0-68DB937EFE55Q38684679-90DF24EA-1943-436A-89B1-61DBFE11C942Q39237821-27A4453E-2EAF-44DA-AE9E-71328A6092F6Q42583265-FCD0E04E-8594-4B1A-B471-F30D0226A573Q45294622-12502073-E305-4BC9-93D1-F9690E939815Q46171847-3ACAA7AD-DA59-473F-A835-893B6E58ACB3Q54572183-3CC17181-AD8E-4870-9100-D032CD5A5AA4
P2860
Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Endocannabinoids acting at CB1 ...... ion in vivo in cirrhotic rats.
@ast
Endocannabinoids acting at CB1 ...... ion in vivo in cirrhotic rats.
@en
type
label
Endocannabinoids acting at CB1 ...... ion in vivo in cirrhotic rats.
@ast
Endocannabinoids acting at CB1 ...... ion in vivo in cirrhotic rats.
@en
prefLabel
Endocannabinoids acting at CB1 ...... ion in vivo in cirrhotic rats.
@ast
Endocannabinoids acting at CB1 ...... ion in vivo in cirrhotic rats.
@en
P2093
P2860
P1476
Endocannabinoids acting at CB1 ...... ion in vivo in cirrhotic rats.
@en
P2093
George Kunos
Judith Harvey-White
Raouf Kechrid
Sándor Bátkai
P2860
P304
P356
10.1152/AJPHEART.00538.2007
P577
2007-06-08T00:00:00Z